COSMO Pharmaceuticals (Switzerland) Performance
| COPN Stock | CHF 63.20 0.40 0.64% |
The firm shows a Beta (market volatility) of 0.28, which signifies not very significant fluctuations relative to the market. As returns on the market increase, COSMO Pharmaceuticals' returns are expected to increase less than the market. However, during the bear market, the loss of holding COSMO Pharmaceuticals is expected to be smaller as well. At this point, COSMO Pharmaceuticals has a negative expected return of -0.34%. Please make sure to confirm COSMO Pharmaceuticals' maximum drawdown, potential upside, kurtosis, as well as the relationship between the value at risk and skewness , to decide if COSMO Pharmaceuticals performance from the past will be repeated at future time.
Risk-Adjusted Performance
0 of 100
Weak | Strong |
Very Weak
Over the last 90 days COSMO Pharmaceuticals SA has generated negative risk-adjusted returns adding no value to investors with long positions. In spite of abnormal performance in the last few months, the Stock's basic indicators remain fairly stable which may send shares a bit higher in December 2024. The latest fuss may also be a sign of long-term up-swing for the venture sophisticated investors. ...more
| Begin Period Cash Flow | 185.9 M | |
| Total Cashflows From Investing Activities | 24.9 M |
COSMO |
COSMO Pharmaceuticals Relative Risk vs. Return Landscape
If you would invest 7,910 in COSMO Pharmaceuticals SA on August 28, 2024 and sell it today you would lose (1,590) from holding COSMO Pharmaceuticals SA or give up 20.1% of portfolio value over 90 days. COSMO Pharmaceuticals SA is generating negative expected returns and assumes 0.9628% volatility on return distribution over the 90 days horizon. Simply put, 8% of stocks are less volatile than COSMO, and 99% of all equity instruments are likely to generate higher returns than the company over the next 90 trading days. Expected Return |
| Risk |
COSMO Pharmaceuticals Market Risk Analysis
Today, many novice investors tend to focus exclusively on investment returns with little concern for COSMO Pharmaceuticals' investment risk. Standard deviation is the most common way to measure market volatility of stocks, such as COSMO Pharmaceuticals SA, and traders can use it to determine the average amount a COSMO Pharmaceuticals' price has deviated from the expected return over a period of time. It is calculated by determining the expected price for the established period and then subtracting this figure from each price point. The differences are then squared, summed, and averaged to produce the variance.
Sharpe Ratio = -0.3532
| Best Portfolio | Best Equity | |||
| Good Returns | ||||
| Average Returns | ||||
| Small Returns | ||||
| Cash | Small Risk | Average Risk | High Risk | Huge Risk |
| Negative Returns | COPN |
Estimated Market Risk
| 0.96 actual daily | 8 92% of assets are more volatile |
Expected Return
| -0.34 actual daily | 0 Most of other assets have higher returns |
Risk-Adjusted Return
| -0.35 actual daily | 0 Most of other assets perform better |
Based on monthly moving average COSMO Pharmaceuticals is not performing at its full potential. However, if added to a well diversified portfolio the total return can be enhanced and market risk can be reduced. You can increase risk-adjusted return of COSMO Pharmaceuticals by adding COSMO Pharmaceuticals to a well-diversified portfolio.
COSMO Pharmaceuticals Fundamentals Growth
COSMO Stock prices reflect investors' perceptions of the future prospects and financial health of COSMO Pharmaceuticals, and COSMO Pharmaceuticals fundamentals are critical determinants of its market performance. Overall, investors pay close attention to revenue and earnings growth, profit margins, and debt levels. These fundamentals can have a significant impact on COSMO Stock performance.
| Return On Equity | 0.0841 | |||
| Return On Asset | 0.0181 | |||
| Profit Margin | 0.45 % | |||
| Operating Margin | 0.25 % | |||
| Current Valuation | 960.99 M | |||
| Shares Outstanding | 16.38 M | |||
| Price To Earning | 95.06 X | |||
| Price To Book | 2.21 X | |||
| Price To Sales | 12.95 X | |||
| Revenue | 65.07 M | |||
| EBITDA | 40.36 M | |||
| Cash And Equivalents | 217.97 M | |||
| Cash Per Share | 14.53 X | |||
| Total Debt | 169.03 M | |||
| Debt To Equity | 35.50 % | |||
| Book Value Per Share | 28.23 X | |||
| Cash Flow From Operations | 12.61 M | |||
| Earnings Per Share | 2.13 X | |||
| Total Asset | 805.56 M | |||
About COSMO Pharmaceuticals Performance
Evaluating COSMO Pharmaceuticals' performance through its fundamental ratios, provides valuable insights into its operational efficiency and profitability. For instance, if COSMO Pharmaceuticals has a high ROA and ROE, it suggests that the company is efficiently using its assets and equity to generate substantial profits, making it an attractive investment. Conversely, if COSMO Pharmaceuticals has a low ROA and ROE, it may indicate underlying issues in asset and equity management, signaling a need for operational improvements. Please also refer to our technical analysis and fundamental analysis pages.
Cosmo Pharmaceuticals N.V., a specialty pharmaceutical company, develops, manufactures, and distributes products for gastroenterology and endoscopy worldwide. Cosmo Pharmaceuticals N.V. was founded in 1997 and is headquartered in Dublin, Ireland. COSMO PHARM operates under Drug Manufacturers - Major classification in Switzerland and is traded on Switzerland Exchange. It employs 306 people.Things to note about COSMO Pharmaceuticals performance evaluation
Checking the ongoing alerts about COSMO Pharmaceuticals for important developments is a great way to find new opportunities for your next move. Stock alerts and notifications screener for COSMO Pharmaceuticals help investors to be notified of important events, changes in technical or fundamental conditions, and significant headlines that can affect investment decisions.| COSMO Pharmaceuticals generated a negative expected return over the last 90 days | |
| About 47.0% of the company shares are held by company insiders |
- Analyzing COSMO Pharmaceuticals' financial statements, including its income statement, balance sheet, and cash flow statement, helps in understanding its overall financial health and growth potential.
- Getting a closer look at valuation ratios like price-to-earnings (P/E) ratio, price-to-sales (P/S) ratio, and price-to-book (P/B) ratio help in understanding whether COSMO Pharmaceuticals' stock is overvalued or undervalued compared to its peers.
- Examining COSMO Pharmaceuticals' industry or sector and how it is performing can give you an idea of its growth potential and how it is positioned relative to its competitors.
- Evaluating COSMO Pharmaceuticals' management team can have a significant impact on its success or failure. Reviewing the track record and experience of COSMO Pharmaceuticals' management team can help you assess the Company's leadership.
- Pay attention to analyst opinions and ratings of COSMO Pharmaceuticals' stock. These opinions can provide insight into COSMO Pharmaceuticals' potential for growth and whether the stock is currently undervalued or overvalued.
Additional Tools for COSMO Stock Analysis
When running COSMO Pharmaceuticals' price analysis, check to measure COSMO Pharmaceuticals' market volatility, profitability, liquidity, solvency, efficiency, growth potential, financial leverage, and other vital indicators. We have many different tools that can be utilized to determine how healthy COSMO Pharmaceuticals is operating at the current time. Most of COSMO Pharmaceuticals' value examination focuses on studying past and present price action to predict the probability of COSMO Pharmaceuticals' future price movements. You can analyze the entity against its peers and the financial market as a whole to determine factors that move COSMO Pharmaceuticals' price. Additionally, you may evaluate how the addition of COSMO Pharmaceuticals to your portfolios can decrease your overall portfolio volatility.